DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07019519

GA22

RecruitingPhase NA

POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS

Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

1

Enrollment

30

estimated

Study population

Healthy volunteers

Key I/E criterion

—

Primary endpoint

•Redistribution of splanchnic blood flow in the vessel mesenteric superior

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07019519
Org study IDH-24030176

Timeline

Milestones

Study start2025-03-15actual
Study first posted2025-06-13actual
Last update posted2025-06-13actual
Primary completion2026-06-30estimated
Study completion2026-09-30estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age50 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

POTS patients:

•Previously diagnosed with POTS in tilt test or active stand-test (either newly diagnosed within last 3 months or in new tilt test/active stand test during screenings visit)
•Reproducible orthostatic intolerance with raise in HR on >30 bpm when standing within 10 minutes of change of supine to standing in age >19 years or >40 bpm in age 18-19 years.
•POTS symptoms/orthostatic intolerance
•Age 18-50
•Waist ratio <180 cm

Exclusion criteria

•Chronic illness
•Metallic implants
•Above 10 alcoholic drinks or week or substance abuse
•Other types of sinus tachycardia or heart disease
•Liverenzymes two times above normal values
•Decreased kidney function eGFR <90 or elevated kreatinkinasis
•Thyroid disease or TSH out of reference
•Uncontrollable low or high blood pressure
•Blood vessels that cannot be visualized on MR
•Any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours

Inclusion Criteria:

•Age 18-50
•Waist ratio <180 cm
•Matched a POTS patient in age, sex and BMI

Exclusion Criteria:

•Chronic illness
•Metallic implants
•Above 10 alcoholic drinks or week or substance abuse
•POTS; other types of sinus tachycardia or heart disease
•Liverenzymes two times above normal values
•Decreased kidney function eGFR <90 or elevated kreatinkinasis
•Thyroid disease or TSH out of reference
•Uncontrollable low or high blood pressure, Orthostatic hypotension
•Blood vessels that cannot be visualized on MR
•Any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
6
Glycemic / diabetes
1
MASH / liver
1
Patient-reported / QoL
1
Safety / tolerability / PK
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint/low confidence

Blood sample for glucose

Time frame:Every 10-20 minutes before and during and after the infusions and MR scans (120 minutes)

descriptive

MASH / liver

1 endpoint
Secondary/protocol endpoint

Blood Flow in the hepatic artery

Time frame:Continuously for 80 minutes/during infusions

descriptive

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Symptomscoring

Time frame:Continously before and during the infusions (120 minutes)

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Blood samples for autoantibodies

Time frame:One measurement at baseline visit

descriptive

Other (unclassified)

6 endpoints
Primary/protocol endpoint/low confidence

Redistribution of splanchnic blood flow in the vessel mesenteric superior artery (MR)

Time frame:Continuously for 80 minutes/during infusions

descriptive

Secondary/protocol endpoint/low confidence

Blood flow in portal vein

Time frame:Continuously for 80 minutes/during infusions

descriptive

Secondary/protocol endpoint/low confidence

Blood Flow in celiac trunk

Time frame:Continuously for 80 minutes/during infusions

descriptive

Secondary/protocol endpoint/low confidence

Blood samples for hormones

Time frame:Every 10-20 minutes before and during and after the infusions and MR scans (120 minutes)

concentration, descriptive

Secondary/protocol endpoint/low confidence

Gastric emptying/Blood sample of paracetamol

Time frame:Every 10-20 minutes before, during and after the infusions and MRI scans (120 minutes)

descriptive

Secondary/protocol endpoint/low confidence

Blood samples for genes

Time frame:One measurement at baseline visit

descriptive

Publications (56)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.